Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Bologna – page 35

885 clinical trials in Bologna, Italy across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Bologna at a glance
885
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

885 trials in Bologna

Open in trial search

Non-small cell lung cancer

Not yet recruiting

Study of zipalertinib plus chemotherapy versus placebo plus chemotherapy in patients with stage IB-IIIA non-small cell lung cancer with uncommon EGFR mutations after surgery

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Taiho Oncology Inc.

Acute myeloid leukaemia

Not yet recruiting

Study of gilteritinib with fludarabine, cytarabine and idarubicin combination therapy in newly diagnosed FLT3-positive acute myeloid leukemia patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Gilteritinib
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Relapsing-remitting multiple sclerosis

Not yet recruiting

Study Comparing ABP 692 and Ocrelizumab for Patients with Relapsing-Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:Amgen Inc.

Rectal cancer

Not yet recruiting

Study on Organ Preservation in Advanced Rectal Cancer Patients Using Bleomycin and Electrochemotherapy After Initial Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bleomycin
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Head and neck cancer

Not yet recruiting

Study on the Effects of Tepotinib and Cetuximab for Patients with Platinum-Resistant Head and Neck Cancer After Immunotherapy Relapse

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

Muscular dystrophy

Not yet recruiting

Study on the Effectiveness of Deflazacort in Treating LMNA-related Congenital Muscular Dystrophy in Adults and Children

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Deflazacort
  • Sponsor:Azienda Ospedaliero Universitaria Pisana

Non-small cell lung cancer stage III

Not yet recruiting

Study on Alectinib for Patients with ALK+ Stage III Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica

Study on Fibrinogen Replacement to Prevent Brain Bleeding in Stroke Patients After Thrombolysis

Not yet recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Human Fibrinogen
  • Sponsor:Azienda Unita Sanitaria Locale Di Bologna

Leiomyosarcoma+5

Not yet recruiting

Study on the Effectiveness and Safety of INT230-6 (Vinblastine Sulfate, Cisplatin) for Adults with Metastatic Soft Tissue Sarcomas

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Intensity Therapeutics Inc.

Prolactin-producing pituitary tumour

Not yet recruiting

Comparison of Surgical Treatment versus Cabergoline in Patients with Newly Diagnosed Microprolactinomas

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cabergoline
  • Sponsor:Azienda Unita Sanitaria Locale Di Bologna

Narcolepsy

Not yet recruiting

Study on TAK-861 for Treating Narcolepsy with Cataplexy in Patients

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:N-{(2S,3R)-4,4-Difluoro-1-(2-Hydroxy-2-Methylpropanoyl)-2-[(2,3',5'-Trifluoro[1,1'-Biphenyl]-3-Yl)Methyl]Pyrrolidin-3-Yl}Ethanesulfonamide
  • Sponsor:Takeda Development Center Americas Inc.

Cardiac arrest

Not yet recruiting

Study on the Safety of Argon and Oxygen Ventilation for Patients Resuscitated from Cardiac Arrest

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Argon
  • Sponsor:Istituto Di Ricerche Farmacologiche Mario Negri

Other cities in Italy

The busiest research cities in the country

All 234 cities in Italy

Clinical research in Bologna

What the registry says about research in the country

01 Hematological Disorders

Innovative research focusing on Immune Thrombocytopenia and various forms of blood cancers including Acute Myeloid Leukemia and Multiple Myeloma. These trials aim to evaluate novel therapeutic approaches and combination treatments.

  • Blood Disorders
  • Leukemia Research
  • Immunology Studies

Studies include evaluation of new compounds and their safety profiles in treating various blood-related conditions.

02 Gastrointestinal Research

Comprehensive studies on inflammatory bowel conditions, focusing on Crohn's Disease and Ulcerative Colitis. Research aims to develop more effective treatments for patients with moderate to severe disease activity.

  • Inflammatory Bowel Disease
  • Treatment Response
  • Disease Management

Trials evaluate both induction therapy and long-term treatment options for gastrointestinal conditions.

03 Neurological Conditions

Investigation of treatments for sleep disorders including Narcolepsy and Idiopathic Hypersomnia, along with research into Chronic Inflammatory Demyelinating Polyneuropathy.

  • Sleep Disorders
  • Neurological Diseases
  • Treatment Safety

Focus on developing safer and more effective therapies for various neurological conditions.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.